Hamideh Yadegari

Dr. Hamideh Yadegari


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2016 in Blood
Verified
Journal Article
Open access
PDF file
HYHamideh Yadegari
Hamideh Yadegari
Arijit BiswasArijit Biswas
Arijit Biswas
MAMohammad Suhail Akhter
Mohammad Suhail Akhter
JDJulia Driesen
Julia Driesen
VIVytautas Ivaskevicius
Vytautas Ivaskevicius
JOJohannes Oldenburg
Johannes Oldenburg
Key Points: This study demonstrates allosteric RNA structure alteration resulting from an exonic variation, thereby interfering with splicing. This study details a novel mechanism by which silent mutation distant to the 5′ splice site could still result in intron retention.

11 July 2024 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
AKAlexander Krahforst
Alexander Krahforst
HYHamideh Yadegari
Hamideh Yadegari
APAnna Pavlova
Anna Pavlova
BPBehnaz Pezeshkpoor
Behnaz Pezeshkpoor
JMJens Müller
Jens Müller
JOJohannes Oldenburg
Johannes Oldenburg
Von Willebrand disease (VWD), the most prevalent hereditary bleeding disorder, results from deficiency of von Willebrand factor (VWF). This large cohort study aims to offer a comprehensive exploration of mutation spectra and laboratory features in quantitative VWF deficiencies, shedding light on genetic underpinnings and genotype-phenotype associations. Our cohort consisted of 221 Caucasian index patients with quantitative VWD, along with 47 individuals whose plasma VWF levels fell within the lower normal boundaries (50-70%). We conducted comprehensive VWF assays and genetic analyses, encompassing VWF gene sequencing, copy number variation investigations, and bioinformatic assessments. Following ISTH-SSC VWF guidelines, 77 index patients characterized as type 1 VWD (VWF:Ag < 30%), 111 as type 1 VWD (VWF:Ag 30-50%), and as 33 type 3 VWD. Mutation detection rates were 88%, 65%, and 92%, respectively. Notably, blood group O overrepresentation was evident in type 1 with VWF:Ag of 30-50%, particularly among mutation-negative patients, suggesting a potential causal role of blood group O. A total of 223 VWF variants, comprising 147 distinct variations, were identified in quantitative VWD patients, of which 57 were novel variants (39%). Additionally, approximately 70% of individuals with VWF levels within the lower normal boundaries (50-70%) displayed VWF variants. Our data advances our understanding of the molecular mechanisms underlying quantitative VWD, offering valuable insights for future research and clinical management. Distinct mutation patterns were observed among subgroups, particularly the contrast between type 1 VWD (VWF:Ag <30%) and type 1 (VWF:Ag 30-50%), an area with limited prior investigation.

7 February 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
HYHamideh Yadegari
Hamideh Yadegari
MJMuhammad Ahmer Jamil
Muhammad Ahmer Jamil
JMJens Müller
Jens Müller
NMNatascha Marquardt
Natascha Marquardt
OROrla Rawley
Orla Rawley
JOJohannes Oldenburg
Johannes Oldenburg
An in-frame heterozygous large deletion of exons 4 through 34 of the von Willebrand factor (VWF) gene was identified in a type 3 von Willebrand disease (VWD) index patient (IP), as the only VWF variant. The IP exhibited severe bleeding episodes despite prophylaxis treatment, with a short VWF half-life after infusion of VWF/factor VIII concentrates. Transcript analysis confirmed transcription of normal VWF messenger RNA besides an aberrant deleted transcript. The IP endothelial colony-forming cells (ECFCs) exhibited a defect in the VWF multimers and Weibel-Palade bodies (WPBs) biogenesis, although demonstrating normal VWF secretion compared with healthy cells. Immunostaining of IP-ECFCs revealed subcellular mislocalization of WPBs pro-inflammatory cargos angiopoietin-2 (Ang2, nuclear accumulation) and P-selectin. Besides, the RNA-sequencing (RNA-seq) analysis showed upregulation of pro-inflammatory and proangiogenic genes, P-selectin, interleukin 8 (IL-8), IL-6, and GROα, copackaged with VWF into WPBs. Further, whole-transcriptome RNA-seq and subsequent gene ontology (GO) enrichment analysis indicated the most enriched GO-biological process terms among the differentially expressed genes in IP-ECFCs were regulation of cell differentiation, cell adhesion, leukocyte adhesion to vascular endothelial, blood vessel morphogenesis, and angiogenesis, which resemble downstream signaling pathways associated with inflammatory stimuli and Ang2 priming. Accordingly, our functional experiments exhibited an increased endothelial cell adhesiveness and interruption in endothelial cell–cell junctions of the IP-ECFCs. In conclusion, the deleted VWF has a dominant-negative impact on multimer assembly and the biogenesis of WPBs, leading to altered trafficking of their pro-inflammatory cargos uniquely, which, in turn, causes changes in cellular signaling pathways, phenotype, and function of the endothelial cells.

Verified
Journal Article
Open access
PDF file
SSSneha Singh
Sneha Singh
MAMohammad Suhail Akhter
Mohammad Suhail Akhter
JDJohannes Dodt
Johannes Dodt
ASAmit Sharma
Amit Sharma
SKSenthilvelrajan Kaniyappan
Senthilvelrajan Kaniyappan
Arijit BiswasArijit Biswas
Arijit Biswas
Congenital FXIII deficiency is a rare bleeding disorder in which mutations are detected in F13A1 and F13B genes that express the two subunits of coagulation FXIII, the catalytic FXIII-A, and protective FXIII-B. Mutations in FXIII-B subunit are considerably rarer compared to FXIII-A. Three mutations in the F13B gene have been reported on its structural disulfide bonds. In the present study, we investigate the structural and functional importance of all 20 structural disulfide bonds in FXIII-B subunit. All disulfide bonds were ablated by individually mutating one of its contributory cysteine’s, and these variants were transiently expressed in HEK293t cell lines. The expression products were studied for stability, secretion, the effect on oligomeric state, and on FXIII-A activation. The structural flexibility of these disulfide bonds was studied using classical MD simulation performed on a FXIII-B subunit monomer model. All 20 FXIII-B were found to be important for the secretion and stability of the protein since ablation of any of these led to a secretion deficit. However, the degree of effect that the disruption of disulfide bond had on the protein differed between individual disulfide bonds reflecting a functional hierarchy/diversity within these disulfide bonds.

18 September 2019 in Haemophilia
Verified
Journal Article
Open access
PDF file
SAShariq Ahmed
Shariq Ahmed
HYHamideh Yadegari
Hamideh Yadegari
ANArshi Naz
Arshi Naz
ABArijit Biswas
Arijit Biswas
UBUlrich Budde
Ulrich Budde
JOJohannes Oldenburg
Johannes Oldenburg
Introduction: Type 3 von Willebrand disease (VWD), a severe autosomal recessive hereditary bleeding disorder, is described by the virtual absence of von Willebrand factor (VWF). In consanguineous populations, for example Pakistan, the disease is reported with a higher incidence rate than the worldwide prevalence.Aims: This study aims to characterize molecular pathology and clinical profile of type 3 VWD cohort of Pakistani origin.Methods: In total, 48 patients were enrolled in the current study. Initially, the index patients (IPs) were evaluated by a standardized questionnaire for recording bleeding manifestations and by performing conventional coagulation tests. The diagnosis of VWD type 3 was confirmed by VWF antigens less than 5 IU/dL. Direct sequencing of VWF gene (VWF) was carried out to identify causative gene variations. We evaluated the potential consequence of novel splice site and missense variations by predictive computational programs and in silico structural analysis.Results: VWF mutations were detected in 46 out of 48 IPs (95.8%), predominantly as homozygous variants. In total, twenty‐nine different gene defects were characterized in this cohort from which 10 (34.5%) are novel. The majority of the mutations were null alleles (66%; including gene conversions, nonsense, splice site variations, small deletions and insertions), and 34% of them were missense substitutions.Conclusion: Herein, we reported for the first time, the pattern of gene defects in Pakistani type 3 VWD cohort. We identified a wide heterogeneous mutation spectrum along with variability in the type of bleeding episodes.

19 October 2023 in Hamostaseologie
Verified
Journal Article
Closed access
PDF file
NSNadine Schwarz
Nadine Schwarz
HYHamideh Yadegari
Hamideh Yadegari
Endothelial colony-forming cells (ECFCs) are endothelial progenitor cells circulating in a limited number in peripheral blood. They can give rise to mature endothelial cells (ECs) and, with intrinsically high proliferative potency, contribute to forming new blood vessels and restoring the damaged endothelium in vivo. ECFCs can be isolated from peripheral blood or umbilical cord and cultured to generate large amounts of autologous ECs in vitro. Upon differentiation in culture, ECFCs are excellent surrogates for mature ECs showing the same phenotypic, genotypic, and functional features. In the last two decades, the ECFCs from various vascular disease patients have been widely used to study the diseases' pathophysiology ex vivo and develop cell-based therapeutic approaches, including vascular regenerative therapy, tissue engineering, and gene therapy. In the current review, we will provide an updated overview of past studies, which have used ECFCs to elucidate the molecular mechanisms underlying the pathogenesis of hemostatic disorders in basic research. Additionally, we summarize preceding studies demonstrating the utility of ECFCs as cellular tools for diagnostic or therapeutic clinical applications in thrombosis and hemostasis.